The Blood Screening Market is expected to grow at a CAGR of 6.9% from 2020 to 2027 to reach $3.56 billion by 2027.
The objective of blood screening is to detect infection markers to prevent the release of infected blood and blood components for clinical use. Blood screening is a diagnostic method used to detect various health conditions, including chronic and infectious diseases. It is carried out in blood banks after collecting donated blood prior to its transfusion to avoid incompatibility issues and transfusion-transmitted infections. Blood tests also enable physicians to diagnose various diseases, administer suitable treatment, and monitor the diseases. Various technologies, such as nucleic acid amplification tests, ELISA, rapid tests, and next-generation sequencing, are utilized for blood screening. The growth of blood screening market is mainly attributed to the increasing number of blood donations and transfusion-related screenings, growing prevalence of infectious & chronic diseases, and increasing government initiatives. Emerging countries and technological advancements are some of the factors that offer significant growth opportunities for players operating in this market. However, the lack of legislation, regulations, and policies related to blood collection and the development of alternative technologies to replace blood screening are expected to hinder the growth of this market.
Here are the top 10 companies operating in Blood Screening Market
Abbott is engaged in discovering, developing, manufacturing, and selling a comprehensive range of health technologies and products. The company offers a wide range of diagnostics, medical devices, nutritional products, and pharmaceuticals. The company operates through four reportable business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers products for blood screening through its Diagnostic Products segment. These segments include core laboratory, molecular diagnostics, point of care, and rapid diagnostics systems.
The company has a wide geographic presence in countries like the U.S., China, Germany, Japan, India, Switzerland, and the Netherlands. Abbott operates through its 92 manufacturing facilities globally, of which 23 facilities are dedicated to developing diagnostic products. Some of the major subsidiaries of Abbott operating in the blood screening market are Abbott Rapid Diagnostics Informatics, Inc. (U.S.), Inverness Medical Innovations SK, LLC (U.S.), Abbott Rapid Diagnostics PTY LTD. (Australia), Abbott Rapid Diagnostics Austria GmbH (Austria), Abbott International Corporation (Canada), Alere (Shanghai) Diagnostics Co., Ltd. (China), and Abbott Rapid Diagnostics S.A.S (France), among others.
bioMérieux designs, develops, manufactures, and markets systems in the field of in-vitro diagnostics for medical and industrial applications. The company is specialized in the diagnosis of infectious diseases and pathologies. The company operates through two major segments, namely, Clinical Applications and Industrial Applications. The company offers products for blood screening through its Clinical Applications segment. This segment includes products and solutions in the field of microbiology, immunoassays, hematology, and molecular diagnostics.
Some of the major subsidiaries of the company are AB bioMérieux (Sweden), bioMérieux Germany, bioMérieux Argentina, bioMérieux Colombia, bioMérieux Brazil, bioMérieux Belgium, bioMérieux Chile, bioMérieux China, bioMérieux Korea, bioMérieux Egypt, bioMérieux Greece, bioMérieux India, bioMérieux Inc. (U.S.), bioMérieux Italy, bioMérieux Japan, bioMérieux Kenya, bioMérieux Malaysia, bioMérieux Philippines, bioMérieux Poland, bioMérieux Portugal, bioMérieux Czech Republic, bioMérieux Russia, bioMérieux South Africa, bioMérieux Suzhou Biotech Co. Ltd. (China), bioMérieux Turkey, bioMérieux U.K., BTF (Australia), and Quercus Scientific NV (Belgium), among others.
bioMérieux has a wide geographic presence in over 44 countries, such as the U.S., Germany, Italy, Spain, France, the U.K., Russia, Turkey, China, India, and others. It serves in more than 160 countries with its large distribution network. The company has 18 bio-industrial sites and 18 research and development centers worldwide.
Bio-Rad Laboratories is engaged in developing, manufacturing, and marketing products for life science research and clinical diagnostic markets. The company manufactures and supplies various products for research institutions, hospitals, public health & commercial laboratories, and biotechnology, pharmaceutical, & applied laboratories. The company operates through two reportable segments—Life Science Research and Clinical Diagnostics. The company provides the products and services for blood screening through both its segments. The Life Science Research segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls that serve clinical laboratories in the global diagnostics market.
Bio-Rad has a direct presence through its manufacturing, research, and distribution facilities, in the western U.S., France, Switzerland, Germany, Belgium, Switzerland, and Singapore. The company also has distribution channels in over 35 countries through subsidiaries, and distributors, and agents. The company’s principal manufacturing and research facilities for the Clinical Diagnostics segment are located in the U.S., Singapore, France, Switzerland, Germany, and Belgium.
Grifols develops, produces, and markets solutions and services for life-science research, clinical trials, and manufacturing pharmaceutical & diagnostic products. The company operates through five reportable business segments, namely, Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The company offers products for blood screening through its Diagnostic segment.
The company operates through 15 industrial facilities with manufacturing in seven different countries and sales in more than 100 countries worldwide. The Diagnostic Division has production centers in the U.S. (Emeryville and San Diego, California), Spain (Barcelona, Vizcaya, and Murcia), Switzerland (Düdingen), Australia (Melbourne), and Brazil (Campo Largo). The major subsidiaries of the company operating in the diagnostics market are Grifols Australia Pty Ltd., Medion Diagnostics AG (Switzerland), Araclon Biotech, S.L. (Spain), Progenika Biopharma, S.A. (Spain), Grifols Diagnostic (Novartis &Hologic) (U.S., Spain, and Hong Kong).
Becton, Dickinson and Company (BD)
Becton, Dickinson and Company (BD) is a global medical technology company involved in medical research and genomics, enhancing the diagnosis of infectious disease and cancer, improving medication management, promoting infection prevention, and equipping surgical and interventional procedures. The company is primarily engaged in developing, manufacturing, and selling a comprehensive range of medical supplies, devices, laboratory equipment, and diagnostic products.
BD operates through three business segments, namely, BD Medical, BD Life Sciences, and BD Interventional. The company provides blood screening products through its BD Life Sciences segment. This segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections, and cancers.
BD manufactures and sells products in the U.S., Europe, the Middle East, Greater Asia, Latin America, and Canada. BD has manufacturing operations outside the U.S. in Bosnia and Herzegovina, Brazil, Canada, China, the Dominican Republic, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Malaysia, Mexico, the Netherlands, Singapore, Spain, and the U.K. The company has a wide distribution network globally, which markets its products through independent distribution channels and directly to hospitals, other healthcare institutions, and independent sales representatives. Some of the major subsidiaries of the company are Bard Access Systems, Inc. (U.S.), Bard Canada Inc (Canada), Bard (Thailand) Limited, Bard Australia Pty. Limited, Bard Benelux N.V. (Belgium), Bard de Espana, S.A. (Spain), Bard European Distribution Center N.V. (Belgium), Bard France S.A.S., Bard Holding GmbH & Co. KG (Germany), Bard Hong Kong Limited, Bard Norden AB (Sweden), Bard Singapore Private Limited, Becton Dickinson India Private Limited, and Becton Dickinson Italia S.p.A.
Meticulous Research in its latest publication on global Blood Screening Market has predicted the growth of 6.9% during the forecast year 2020 to 2027.
F. Hoffmann-La Roche
F. Hoffmann-La Roche is a research-based healthcare company involved in pharmaceuticals and diagnostics. The company is engaged in manufacturing pharmaceutical products and providing solutions for diagnostics tests. Roche operates through two major business segments, namely, Pharmaceuticals and Diagnostics. The company’s Diagnostic division consists of four business areas: Centralized and Point of Care Solutions, Molecular Diagnostics, Tissue diagnostics, and Diabetes Care. The Molecular Diagnostics business area of the Diagnostic business division develops, manufactures equipment and reagents used in the blood screening market.
The company has its major geographic presence in North America, Europe, Asia, Latin America, Africa, Australia, and New Zealand. The company has 26 manufacturing sites and 30 R&D sites for its pharmaceutical and diagnostics business worldwide.
Founded in 1993 and headquartered in California, U.S, Boster Biological is engaged in developing, manufacturing, and distributing antibodies and ELISA kits and other life science products and services for researchers worldwide. The company has a portfolio of more than 2,000 ELISA kits and over 16,000 antibodies for blood screening purposes.
The company has its distribution network in 50 countries, extending across countries in Asia, Europe, North America, Central and South America, Australia, and Africa.
Danaher is primarily involved in designing, manufacturing, and marketing medical, professional, industrial, and commercial products and services for various end users. The company operates through four business segments, namely, Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions. Through its Diagnostics business segment, the company operates in the blood screening market. This segment offers immunoassay systems, chemistry systems, hematology products, microbiology products, molecular diagnostics products, and automation systems to screen blood and other body fluids.
The company’s research and development, manufacturing, sales, distribution, service, and administrative facilities are located in more than 60 countries worldwide. Danaher has its presence in the U.S., China, Germany, Japan, and other countries. The company’s manufacturing facilities for the Diagnostics segment are majorly located in North America, Europe, Asia, and Australia. The company sells its products through direct sales personnel and independent distributors. Some of the major subsidiaries of the company are Beckman Coulter, Inc. (U.S.) Cepheid (U.S.), HemoCue AB (Sweden), and Radiometer Medical ApS (Denmark).
Founded in 2007 and headquartered in Texas, U.S., CUSABIO TECHNOLOGY is engaged in the research, production, sales, and distribution of ELISA kits, Exosome isolation kits, antibodies, proteins, and related reagents.
CUSABIO has a global presence in more than 90 countries and a wide channel of 150 distributors worldwide. The company has facilities in the U.S. and China and a distribution network in Africa, Asia, Europe, North America, Australia, and South America.
Demeditec Diagnostics GMBH
Founded in 1987 and headquartered in Kiel, Germany, Demeditec is engaged in the manufacturing and supplying in-vitro diagnostic kits. The company has an extensive product portfolio of ELISA and RIA systems covering the areas of diagnostics, endocrinology, infectious diseases, autoimmunity, biogenic amines, tumor markers, and food analytics.
The company has a worldwide presence, and its customers include private laboratories, hospitals, universities, and other research institutions and pharmaceutical companies.
Popular Mentions: Thermo Fisher Scientific, Inc., and Siemens Healthneers
Amidst this crisis, Meticulous Research® is continuously assessing the impact of the COVID-19 pandemic on various sub-markets and enables global organizations to strategize for the post-COVID-19 world and sustain their growth. Let us know if you would like to assess the impact of COVID-19 on any industry here- https://www.meticulousresearch.com/download-sample-report/cp_id=5164
Authoritative Research on the Blood Screening Market – Global Opportunity Analysis and Industry Forecast (2020-2027)
Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:
- Recent financial performance
- Key products
- Significant company strategies
- Partnerships and acquisitions
- The Impact of COVID-19 on the Blood Screening Market
The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.
Please download report pages and learn more : https://www.meticulousresearch.com/download-sample-report/cp_id=5164